The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Boehringer Ingelheim
LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
 
Heinz-Josef Lenz
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim (Inst)
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Taiho Pharmaceutical
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Takeda
Research Funding - Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; Pfizer; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Zohra Oum'Hamed
Employment - Boehringer Ingelheim
 
Soetkin Vlassak
No Relationships to Disclose
 
Mouna Sassi
Employment - Boehringer Ingelheim
 
Eric Van Cutsem
Research Funding - Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)